Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Cerebrospinal fluid autoantibodies target the brain in some COVID-19 patients

A study conducted by German researchers has shown that the neurological symptoms observed in some patients with coronavirus disease 2019 (COVID-19) may be caused by autoantibodies targeting the brain.

7 Jul 2020

Evolutionary snapshot reveals genetic stability of SARS-CoV-2

A multinational study currently available on the bioRxiv preprint server shows that in the early large genome of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) only a handful of amino acids are exchanged, implying a relatively low mutation rate and selection pressure.

7 Jul 2020

SARS-CoV-2 spike protein hidden as pH changes

Now, a new study published on the preprint server bioRxiv in July 2020 reports the role of pH in helping the virus escape neutralization by antibodies, by inducing a key conformational switch.

7 Jul 2020

New technique evaluates connectivity of brain networks in COVID-19 patients

Many patients with severe coronavirus disease in 2019 (COVID-19) remain unresponsive after surviving critical illness.

7 Jul 2020

Faulty immune response to SARS-CoV-2 one of the main causes of death

A new study published on the preprint server medRxiv in July 2020 describes the organ and tissue-specific spread of the virus causing the current COVID-19 pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 Jul 2020

SARS-CoV-2 detected in Santiago, Chile wastewater with very little loss of viral RNA

A preliminary report from Chile describes the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in sewage as a sensitive method to assess the circulation of viruses within a community.

7 Jul 2020

Viral and bacterial co-infections are pervasive in severe COVID-19 patients

A large group of researchers from China recently characterized microbial co-infections in the respiratory tract of hospitalized coronavirus disease (COVID-19) patients and demonstrated a high prevalence of both viral and bacterial co-infections – particularly in individuals presenting with severe disease.

6 Jul 2020

Airborne spread of SARS-CoV-2 possible and should not be ignored

Researchers at the National Institute for Public Health and the Environment in the Netherlands say that airborne transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is possible and should not be discounted.

6 Jul 2020

COVID-19 risk halved when airplane middle seats empty, expert statistician says

As the coronavirus cases skyrocket, many countries have started to ease lockdown measures to save the ailing economy. Restaurants, malls, recreational centers, and transportation are slowly returning to normal operations. However, one of the most heavily impacted sectors amid the pandemic is the aviation industry.

6 Jul 2020

WHO urged to recognize airborne transmission of COVID-19

Now, a team of international scientists, including 239 health experts from 32 countries, has written an open letter to the WHO urging the organization to revise its recommendations for the spread of SARS-CoV-2, due to mounting evidence that the disease is airborne for more extended periods than the WHO advisory.

6 Jul 2020

Oxford COVID-19 vaccine trials move to stage 3 human trials

The technical name of the vaccine is ChAdOx1 nCoV-19 (AZD1222), as it is made from a virus called ChAdOx1, which is a weakened and non-replicating version of a common cold virus (adenovirus). The vaccine has been engineered to express the SARS-CoV-2 spike protein.

5 Jul 2020

Research suggests protective effect of influenza vaccine against COVID-19 severity and mortality

A new study involving over 92,000 patients with COVID-19 in Brazil shows that the odds of severe disease, ventilatory support requirement, and death are reduced with a recent trivalent flu vaccine. This seems to indicate that these vaccines should be used as widely as possible to reduce the risk of severe COVID-19, especially among high-risk groups. The study is published on the preprint server medRxiv* in June 2020.

5 Jul 2020

Diagnosis of COVID-19 by RT-LAMP assay in 25 minutes

Even as COVID-19 continues its inexorable march, taking hundreds of thousands of lives and causing nearly 11 million cases, the diagnosis of the infection is still not sensitive or specific enough. Now, a new study by scientists at the Francis Crick Institute and published on the preprint server medRxiv...

3 Jul 2020

Mutated European strain of coronavirus more contagious but less potent

The coronavirus pandemic is far from over as it actively spreads across the globe. The infection toll has reached a staggering 10.84 million people since it emerged in late December 2019 in Wuhan City, China. The virus that has left the city has now spread to 188 countries and territories and has mutated, becoming more infectious.

3 Jul 2020

Markers of vascular damage in COVID-19

A new study by researchers at Yale University and published on the preprint server medRxiv reports on the plasma levels of biomolecules that reflect vascular damage in COVID-19.

2 Jul 2020

Effectiveness of NPI's in COVID-19 - conclusions are predictable, NPI's work

Now, a new study published on the preprint server medRxiv* looks at how the effects of these NPIs can be quantified in order to keep the public health response to COVID-19 at an adequate level. While NPIs are known to reduce the peak of the infections, in general, the researchers wanted to quantify different components separately.

2 Jul 2020

Researchers find possible cause for SARS-CoV-2 reactive T cells in uninfected individuals

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) -2, leading to severe pneumonia, acute respiratory distress syndrome, and death in a sizable minority of cases. However, the most significant number are asymptomatic or have only mild infection from which they rapidly recover.

2 Jul 2020

Pfizer/BioNTech COVID-19 vaccine shows promise - virus neutralizing antibodies achieved

In a recent medRxiv* paper, a research group from the U.S. and Germany showed a robust immunogenic response and a promising safety profile of the novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) – actively encouraging its accelerated clinical development and potential rapid production.

2 Jul 2020

New platform prioritizes synergistic drug combinations against SARS-CoV-2

Researchers in the U.S. have used a new web-based platform to help identify synergistic and antagonistic drug combinations and their underlying mechanisms of action in the context of coronavirus disease 2019 (COVID-19).

2 Jul 2020

Structure of the full SARS-CoV-2 RNA genome in infected cells

The current COVID-19 pandemic caused by a single-stranded RNA virus, thought to have jumped across species barriers to infect humans, has spread rapidly across the globe infecting over 10 million individuals. The virus, now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative agent of COVID-19 disease. COVID-19 disease is a respiratory illness where symptoms can range from very mild to severe and include fever, coughing, a sore throat, and shortness of breath.

2 Jul 2020